- Conditions
- Meningitis, Meningococcal
- Interventions
- Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 2 Months to 2 Months
- Enrollment
- 4,545 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 53
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–43
of 43
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
- Interventions
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 15 Months
- Enrollment
- 852 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 49
- States / cities
- Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more
- Conditions
- RSV Immunization
- Interventions
- RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 12 Months
- Enrollment
- 2,226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
- Conditions
- Tetanus, Diphtheria, Pertussis, Measles, Polio
- Interventions
- Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 3,372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more
- Conditions
- Infections, Meningococcal
- Interventions
- Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,797 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more
- Conditions
- Chickenpox
- Interventions
- Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 911 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more
- Conditions
- Pneumococcal Immunization
- Interventions
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 19 Months
- Enrollment
- 950 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more
- Conditions
- Varicella
- Interventions
- VARIVAX® PE34 Process, VARIVAX® 2016 Commercial Process, M-M-R II®
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 12 Months to 23 Months
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 32 more
- Conditions
- Chickenpox
- Interventions
- Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 1,840 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 59
- States / cities
- Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Interventions
- GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 478 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 11
- States / cities
- Antioch, California • Daly City, California • Hayward, California + 7 more
- Conditions
- Measles-Mumps-Rubella
- Interventions
- Priorix, M-M-R II, Kinrix, ProQuad
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 4,011 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Benton, Arkansas + 44 more
- Conditions
- Adolescent Health Services, Immunization
- Interventions
- Assessment , Feedback, Incentives, and eXchange Program
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Not listed
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Raleigh, North Carolina
- Conditions
- Haemophilus Influenzae Type b, Neisseria Meningitidis
- Interventions
- GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar, M-M-R II, Varivax
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 4,021 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more
- Conditions
- Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
- Interventions
- GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®, Havrix®, Prevnar®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 1,259 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 45
- States / cities
- Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
- Interventions
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV), Routine paediatric vaccine - Hepatitis A
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 9 Months to 12 Months
- Enrollment
- 1,378 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 68 more
- Conditions
- Pneumococcal Immunization
- Interventions
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 580 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Hollywood, Florida • Miami, Florida + 13 more
- Conditions
- Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
- Interventions
- MMRVNS, MMRV
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 15 Months to 6 Years
- Enrollment
- 1,209 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Walnut Creek, California • Miami, Florida + 12 more